This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical



Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact



HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
Confirmed Protection Against Diverse MenB Strains with 2 Doses1While you don't know which strains your patients may encounter, TRUMENBA is the ONLY MenB vaccine with confirmed evidence of diverse strain protection
(14 strains).1*
Learn more about diverse strain protection Loading

Based on demonstrated effectiveness against 14 diverse strains representative of prevalent MenB strains.

Pfizer TruSupport
  • Ordering options
  • Patient coverage confirmation
  • Essential tools
  • Resources for your practice
Find out more about TruSupport
CDC recommendations

MenB vaccination is part of the CDC 16-year-old vaccination platform.2

Read the recommendations

CDC=Centers for Disease Control and  Prevention.

The science behind TRUMENBA

Only TRUMENBA targets both subfamilies, A and B, of fHbp.1,3

See the science Loading

fHbp=factor H binding protein.

TRUMENBA clinical studies

TRUMENBA is the only MenB vaccine that demonstrates coverage of diverse MenB strains by targeting both subfamilies, A and B, of fHbp.1,3

See the data Loading
Contact your Pfizer Sales Representative or call a Vaccine Specialist at
References:TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021. Centers for Disease Control and Prevention website. Accessed October 21, 2021. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.

Please see full Prescribing Information.

OK. We'll need you to sign in before we can determine if you are aligned with a sales representative. 

If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.

Would you like to sign in now?